News and Events
IPAC White Paper on Patient Journey: A Multi-Stakeholder Approach to Minimizing the Environmental Impact of Inhaled Therapies and Improving Patient Care - A Proposal for Discussion. Click here to read the White Paper.
IPAC Submits Comments to Dr. Thérèse Coffey, MP, sharing IPAC’s observations on the House of Commons Environmental Audit Committee – UK Progress on Reducing F-Gas Emissions Report (18 April 2018 – Fifth Report of Session 2017-19) (29 May 2018). Click here to read IPAC's Comments.
IPAC Congratulates the Montreal Protocol Parties on 30 Years of Outstanding Leadership. IPAC congratulates the Parties on three decades of dedication to healing the ozone layer, while recognizing technological, economic, and health realities. The Montreal Protocol Parties’ focus on pragmatic, sustainable solutions is an inspiring model for other international frameworks. IPAC commends the Montreal Protocol Parties, Technological and Economic Assessment Panel – and the Medical and Chemical Technical Options Committee – for their expertise, hard work, and patience in providing sound guidance and recommendations to the Parties over thirty years. Click here to read IPAC's Statement.
Who We Are
IPAC was formed almost three decades ago in response to the phase out of CFCs in critical inhalation products under the mandate of the Montreal Protocol on Substances that Deplete the Ozone Layer. IPAC is the premier organization on inhaled products and environmental policy issues and serves as a resource for policymakers and regulators around the world. IPAC’s members research, develop and manufacture metered dose inahlers (MDIs) for the treatment of respiratory illnesses, such as asthma and chronic obstructive pulmonary disease.
With the transition away from CFC MDIs successfully completed, IPAC is focused on preserving the long-term availability of pharmaceutical-grade HFCs – the environmental solution to CFCs in MDIs – for patient use. IPAC closely monitors legislative and policy developments on HFCs and climate change and engages regulators and policymakers on the critical patient care aspects of HFC MDIs.
IPAC recommends that any phase down of HFCs is structured to ensure that adequate, safe, and secure supplies of HFCs remain available to meet patient need over the long term.
"Any consideration of policy measures to control HFCs should carefully assess patient health implications with the goals of ensuring patient health and maintaining a range of therapeutic options."
Protecting Patients and Preserving the Environment:
A Global Accomplishment
IPAC congratulates the Parties to the Montreal Protocol on the completion of the transition away from CFC Metered Dose Inhalers (MDIs) and welcomes the Ozone Secretariat’s announcement that CFC MDIs will disappear completely by end of 2016. This is an impressive achievement. IPAC commends the Parties and the Medical Technical Options Committee on their diligence and commitment in managing this important process over close to three decades.
IPAC commends the Parties to the Montreal Protocol for achieving consensus in Kigali, Rwanda on a path forward for HFCs. Importantly, the Kigali Amendment is a phase down approach recognizing the need to ensure HFCs remain available for MDIs and other sectors where cost-effective and technically feasible alternatives are not available.